Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Lengyelország
15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Gliwice, Katowice, Lublin, Olsztyn, Slupsk, Wroclaw
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 3. fázisTaking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Poznan, Skorzewo, Wałbrzych, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - 1. fázisTaking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Cracow, Katowice, Skorzewo, Warsaw
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - 2/3. fázisTaking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Cracow, Katowice, Slupsk, Walbrzych, Warsaw
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - 2. fázisTaking peopleA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Where
- Cracow, Gdansk, Katowice, Nowy Sacz, Skorzewo, Walbrzych, Warsaw
- Életkor
- 18 év and over
- People
- 594 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00 - 1. fázisTaking peopleA Study of ARC-02 in B-cell NHL
- Where
- Cracow, Katowice, Skorzewo, Warsaw
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Bydgoszcz, Cracow, Koszalin, Warsaw
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 1/2. fázisTaking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Gdansk, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - 1. fázisTaking peopleDose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- Where
- Krakow, Lodz, Lublin, Skorzewo
- Életkor
- 18 év and over
- People
- 85 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00 - 1. fázisTaking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Katowice, Krakow, Lublin, Skórzewo, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - 2. fázisTaking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Wroclaw
- Életkor
- 18 év to 70 év
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - 1. fázisTaking peoplePhase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).
- Where
- Wroclaw
- Életkor
- 18 év and over
- People
- 18
- Run by
- Wroclaw Medical University
See details and how to join2024-519318-30-00 · EU 2024-519318-30-00 - 1. fázisTaking peopleStudy of SGR-1505 in Mature B-Cell Neoplasms
- Where
- Gdansk, Lodz, Warsaw
- Életkor
- 18 év and over
- People
- 98 worldwide
- Run by
- Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00 - 2. fázisTaking peopleDPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Where
- Gdynia, Legnica, Olsztyn, Skórzewo, Warsaw
- Életkor
- 18 év and over
- People
- 102 worldwide
- Run by
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617 - 1/2. fázisTaking peopleSafety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Where
- Gdansk, Gliwice, Krakow, Wroclaw
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT04502394